
|Videos|January 14, 2015
Important Considerations in Iron Chelation Therapy
Advertisement
Episodes in this series

Any patient receiving regular blood transfusions will need to have the excess iron in their body removed, says Thomas D. Coates, MD. For patients who receive iron chelation therapy, careful monitoring is critical, as renal and neurologic side effects can occur. Iron chelation therapy can also result in low white blood cell counts, adds Coates. In children, it is important to recognize that iron is essential to their growth and development.
In Coates’ opinion, regulating the dose of an iron chelating agent should be based more on tolerance for the medication than on the body’s iron levels. Poor adherence remains an issue with these agents, adds Coates.
Advertisement
Related to this article

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
5


























